Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)
Clinical trial NCT05767632 · COMPLETED
Trial details
- NCT number
- NCT05767632
- Sponsor
- Genuine Research Center, Egypt
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-30
- Primary completion
- 2022-07-25
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.